Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Non-Small Cell Lung Cancer ALK+ or ROS1+ (Jan 2021)

Posted by Matt Breese on Jan 8, 2021

Find me on:

According to our recent payer coverage analysis for non-small cell lung cancer ALK+ or ROS1+ treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for non-small cell lung cancer ALK+ or ROS1+ treatments shows that under the pharmacy benefit, about 75% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-NSCLC ALK+ROS1+-1Q2021Data snapshot as of Q1 2021

Trends: Competition is growing, with six different drugs from four different manufacturers targeting these gene mutations in patients with NSCLC.  

To read the full Reality Check on Non-Small Cell Lung Cancer ALK+ or ROS1+ treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 

reality-check-thumbnail-v1-1.png

View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing